Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

The 17q23 amplicon containing the WIP1 oncogene is frequently amplified in HER2+ breast cancer. Here they find MIR21 to be present in WIP1-containing amplicons, and report nanoparticle based co-delivery of WIP1 and miR-21 inhibitors to be effective in trastuzumab-resistant HER2+ breast cancer.

Guardado en:

Detalles Bibliográficos
Autores principales:	Yunhua Liu, Jiangsheng Xu, Hyun Ho Choi, Cecil Han, Yuanzhang Fang, Yujing Li, Kevin Van der Jeught, Hanchen Xu, Lu Zhang, Michael Frieden, Lifei Wang, Haniyeh Eyvani, Yifan Sun, Gang Zhao, Yuntian Zhang, Sheng Liu, Jun Wan, Cheng Huang, Guang Ji, Xiongbin Lu, Xiaoming He, Xinna Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/aeb67f3a601a4cf6a9ea4388b746953b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aeb67f3a601a4cf6a9ea4388b746953b
record_format	dspace
spelling	oai:doaj.org-article:aeb67f3a601a4cf6a9ea4388b746953b2021-12-02T16:49:51ZTargeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer10.1038/s41467-018-07264-02041-1723https://doaj.org/article/aeb67f3a601a4cf6a9ea4388b746953b2018-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-07264-0https://doaj.org/toc/2041-1723The 17q23 amplicon containing the WIP1 oncogene is frequently amplified in HER2+ breast cancer. Here they find MIR21 to be present in WIP1-containing amplicons, and report nanoparticle based co-delivery of WIP1 and miR-21 inhibitors to be effective in trastuzumab-resistant HER2+ breast cancer.Yunhua LiuJiangsheng XuHyun Ho ChoiCecil HanYuanzhang FangYujing LiKevin Van der JeughtHanchen XuLu ZhangMichael FriedenLifei WangHaniyeh EyvaniYifan SunGang ZhaoYuntian ZhangSheng LiuJun WanCheng HuangGuang JiXiongbin LuXiaoming HeXinna ZhangNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Yunhua Liu Jiangsheng Xu Hyun Ho Choi Cecil Han Yuanzhang Fang Yujing Li Kevin Van der Jeught Hanchen Xu Lu Zhang Michael Frieden Lifei Wang Haniyeh Eyvani Yifan Sun Gang Zhao Yuntian Zhang Sheng Liu Jun Wan Cheng Huang Guang Ji Xiongbin Lu Xiaoming He Xinna Zhang Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
description	The 17q23 amplicon containing the WIP1 oncogene is frequently amplified in HER2+ breast cancer. Here they find MIR21 to be present in WIP1-containing amplicons, and report nanoparticle based co-delivery of WIP1 and miR-21 inhibitors to be effective in trastuzumab-resistant HER2+ breast cancer.
format	article
author	Yunhua Liu Jiangsheng Xu Hyun Ho Choi Cecil Han Yuanzhang Fang Yujing Li Kevin Van der Jeught Hanchen Xu Lu Zhang Michael Frieden Lifei Wang Haniyeh Eyvani Yifan Sun Gang Zhao Yuntian Zhang Sheng Liu Jun Wan Cheng Huang Guang Ji Xiongbin Lu Xiaoming He Xinna Zhang
author_facet	Yunhua Liu Jiangsheng Xu Hyun Ho Choi Cecil Han Yuanzhang Fang Yujing Li Kevin Van der Jeught Hanchen Xu Lu Zhang Michael Frieden Lifei Wang Haniyeh Eyvani Yifan Sun Gang Zhao Yuntian Zhang Sheng Liu Jun Wan Cheng Huang Guang Ji Xiongbin Lu Xiaoming He Xinna Zhang
author_sort	Yunhua Liu
title	Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
title_short	Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
title_full	Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
title_fullStr	Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
title_full_unstemmed	Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
title_sort	targeting 17q23 amplicon to overcome the resistance to anti-her2 therapy in her2+ breast cancer
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/aeb67f3a601a4cf6a9ea4388b746953b
work_keys_str_mv	AT yunhualiu targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT jiangshengxu targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT hyunhochoi targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT cecilhan targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT yuanzhangfang targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT yujingli targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT kevinvanderjeught targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT hanchenxu targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT luzhang targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT michaelfrieden targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT lifeiwang targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT haniyeheyvani targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT yifansun targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT gangzhao targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT yuntianzhang targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT shengliu targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT junwan targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT chenghuang targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT guangji targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT xiongbinlu targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT xiaominghe targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer AT xinnazhang targeting17q23amplicontoovercometheresistancetoantiher2therapyinher2breastcancer
_version_	1718383178826121216

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

Ejemplares similares